Articles tagged with Glaucoma
A new study by the University of Bradford reveals that people with early-stage glaucoma see contrast in a similar way to those without it, despite measurable vision loss. This underlines the importance of regular eye checks to detect glaucoma before damage is established.
A new study in rodents suggests that star-shaped brain cells called astrocytes may be responsible for killing nerve cells in glaucoma. The study found that increased pressure drove astrocytes to release toxins that killed neurons, highlighting a potential target for treating the disease.
Researchers used a 'disease in a dish' stem cell model to examine the mechanism behind retinal ganglion cell degeneration in glaucoma. The study found that cells from individuals with a genetic risk allele for glaucoma were stalled at an immature stage, making them more vulnerable to degeneration.
Using human stem cell models, researchers identified deficits within cells damaged by glaucoma and found that correcting genetic mutations could slow disease progression. They also discovered dysfunction in autophagy, a process that removes damaged cells, which correlated with neurodegeneration.
A study identified a rare genetic variant in the ANGPTL7 gene that lowers intraocular pressure and significantly reduces the risk of glaucoma. The findings open up new therapeutic possibilities for treating this eye disease.
A new AI-supported test, called DARC, can detect glaucoma progression 18 months earlier than the current gold standard method. The technology involves injecting a fluorescent dye into the bloodstream and illuminating damaged retinal cells using artificial intelligence.
A new study shows a common eye condition, glaucoma, can be successfully treated with gene therapy using a single injection, providing additional treatment options and benefits. Glaucoma affects over 64 million people worldwide and is a leading cause of irreversible blindness.
A retrospective observational study of ophthalmologists' experiences with familial amyloid polyneuropathies (FAP) reveals the challenges of treating this rare disease, particularly in maintaining eyesight despite liver transplants. The study aims to share knowledge and best practices with other researchers and doctors worldwide.
Researchers from City, University of London developed a software tool to simulate glaucoma's impact on daily life, using commercially available head-mounted displays (HMDs). The study found that participants with simulated visual impairment performed tasks slower and made more movements compared to those without impairment.
Neuroscientists at the University of South Florida have developed a method to regulate eye pressure, which is sufficient to cause and explain glaucoma. The new technique enables direct knowledge and control of eye pressure, removing experimental variability and enabling systematic studies.
A new observational study examines how glaucoma treatment and follow-up are managed in a prison clinic, with findings on medication adherence being highlighted as an area of concern. The research sheds light on the challenges faced by prisoners with this common eye condition.
Researchers have identified 107 genes that increase a person's risk of developing glaucoma, a leading cause of irreversible blindness globally. The new test uses genetic information from tens of thousands of people worldwide to accurately predict glaucoma risk using a single blood or saliva sample.
Researchers at the University of South Florida have discovered a novel feedback pathway from the brain to the eye that modulates eye pressure. This breakthrough finding may lead to new treatments for glaucoma by exploiting the modulatory mechanisms of the drainage control system.
Global glaucoma burden is higher in men than women, with DALY rates decreasing from 1990 to 2017. Sex differences are also influenced by age and socioeconomic status.
A study found that only a fifth of UK shoppers know their intraocular pressure, a major risk factor for primary open angle glaucoma. Advertising the eye health check alongside blood pressure testing increased participation.
A new UCL-led study found that living in a more polluted area is associated with a greater likelihood of having glaucoma, a debilitating eye condition that can cause blindness. People in areas with high levels of fine particulate matter pollution were 6% more likely to report having glaucoma than those in less-polluted areas.
Researchers at Indiana University have used a technique originally developed to view stars more clearly to take the first undistorted images of the trabecular meshwork, a part of the eye involved in glaucoma. This breakthrough could lead to improved treatment for the condition, which affects millions worldwide.
Researchers have successfully regenerated human retinal ganglion cells in a laboratory dish using lessons learned from rodent models. The discovery could lead to new methods of screening for drugs and genes impacted by glaucoma, potentially offering hope for vision loss patients.
A recent study by Jae Hee Kang et al., published in JAMA Ophthalmology, initially reported a significant association between long-term statin use and reduced primary open-angle glaucoma risk. However, due to serious coding errors, the findings were later retracted.
Scientists are working on a new method to detect glaucoma by analyzing the protein profile in eye fluid. They compare this profile with clinical data, including images of optic nerve damage, to identify a 'proteomic signature' for glaucoma. The goal is to develop a reliable diagnostic tool and monitor patients' progress.
A recent study of over 136,000 adults found that high cholesterol levels are associated with an increased risk for primary open-angle glaucoma. In contrast, longer use of statins was linked to a lower risk of POAG, particularly among those 65 and older.
Researchers pinpointed the premelanosome protein (PMEL) gene as the cause of pigmentary glaucoma, a condition that affects 150,000 people in North America. The study found that mutations in this gene lead to vision loss and blindness if left untreated.
A partnership between Kellogg Eye Center and the University of Michigan used radio-frequency identification (RFID) to track patient wait times and enhance time spent at the doctor's office. The smart clinic model improved efficiency and boosted transparency, allowing doctors to monitor patients' movements and provide timely reassurance.
Researchers at Indiana University found that CBD worsens glaucoma by raising eye pressure in mice. The study suggests a need to understand potential side effects of CBD, especially in children.
A study of 100 patients found that linking medication reminders to electronic health records (EHRs) improved adherence among glaucoma patients. The reminders were delivered via text or voice message for three months and were reported useful by 74% of participants.
Researchers have developed a painless and efficient alternative to current treatment methods for eye diseases, using biodegradable microneedles that deliver drugs into the eye. The patch has been shown to be 90% more effective than eye drops in alleviating corneal vascularisation.
Stephen Christiansen, MD, received a Senior Achievement Award for his significant contributions to ophthalmology and pediatrics. Babak Eliassi-Rad, MD, was awarded an Achievement Award for his research and clinical work on glaucoma and cataract.
Researchers created a new drainage device that combats biofouling by using microtechnology, allowing for a more reliable and effective implant for treating glaucoma. The device varies flow resistance to customize treatment for each patient, helping to save eyesight.
A new study published in JAMA Ophthalmology found that traditional glaucoma tests often underestimate the severity of central vision loss. Researchers developed a finer visual field test to assess macular damage and found it can improve diagnosis at no extra cost.
A new study published in the Journal of Glaucoma found that mindful meditation practice significantly lowers intraocular pressure, reducing stress-related biomarkers and improving quality-of-life. Meditation also positively influences other indicators, such as reduced cortisol levels and increased brain-derived neurotrophic factors.
Researchers identified new biomarkers that can detect glaucoma at an early stage, enabling early intervention. The study's findings suggest that these biomarkers may inhibit neurodegeneration in the optic nerve and retina.
A new technology to detect corrosion and erosion in pipelines can prevent catastrophic explosions at power plants. Dr. Piero Rizzo's project aims to develop a device that monitors pipeline conditions continuously and remotely.
A recent study suggests that glaucoma is not just a pressure-related disease, but also an autoimmune disorder caused by the immune system attacking retinal cells. The researchers found that T cells, which normally target foreign substances, are responsible for progressive retinal degeneration in glaucoma.
Researchers discover immune cells in eye contribute to progressive vision loss from glaucoma. Elevated eye pressure triggers autoimmune response attacking neurons, leading to optic nerve degeneration and permanent vision loss. The findings offer a promising new target for future therapies.
Researchers have developed turmeric-based eye drops that can reduce retinal cell loss in rats with glaucoma. The treatment shows promise for diagnosing Alzheimer's disease and has been found to be well-tolerated.
Researchers found that variants of the LOXL1 gene are associated with increased levels of the protein, which clogs the outflow pathway and causes high pressure in the eye. The long non-coding RNA lncLOXL1 regulates the gene's expression and is thought to contribute to the disease progression.
Researchers aim to enhance neuron protection in glaucoma patients by activating the sigma 1 receptor, potentially increasing long-term protection. The S1R agonists have shown promising results in protecting retinal ganglion cells and may offer a new treatment strategy for glaucoma.
A study of 140,000 people identified 133 genetic variants that could help predict the risk of developing glaucoma. These genetic markers can be measured as early as birth and may allow for earlier diagnosis and treatment.
A ketogenic diet has been found to protect retinal cells from degeneration in a mouse model of glaucoma, increasing energy availability. The study suggests that a ketogenic diet may help maintain vision in patients with glaucoma.
Researchers at Caltech create eye implant inspired by butterfly wings' nanostructures, reducing measurement error and biofouling. The implant's surface flexes to measure intra-eye pressure, providing accurate readings regardless of angle.
Researchers at University of British Columbia developed a new hydrogel-based eye drop that effectively treats glaucoma by quickly absorbing and reaching the back of the eye. The treatment, which contains cannabigerolic acid, was tested on donated pig corneas and showed promising results.
A new 'pen camera' called GonioPEN makes it easier to diagnose patients with glaucoma by detecting the type of glaucoma in a faster and cheaper manner. It causes negligible discomfort and allows doctors or trained technicians to capture high-resolution images of the eye drainage canal with minimal contact.
A new IRIS Registry-powered study explores racial and gender outcomes with minimally invasive glaucoma surgery, aiming to increase quality care for diverse patient groups. The research seeks to assess the real-world demographic differences in MIGS use, safety, and effectiveness.
Researchers have identified two distinct types of vision-degrading glaucoma and pinpointed key genes associated with the condition. The study also suggests that exercise can help reduce eye pressure and provides a potential new point of intervention for treating glaucoma.
Two novel ocular hypotensive agents, netarsudil and latanoprostene bunod, have been approved for use in humans, reducing intraocular pressure with lasting results. These breakthrough drugs also show promise for treating dry eye disease and delivering ophthalmic drugs via microneedles.
Researchers discovered that individual neurons fight back to maintain signaling between brain regions, slowing disease progression in glaucoma. This finding suggests a potential new therapeutic approach to preserve vision and slow degeneration in age-related neurodegenerative disorders.
A study published in PLOS Genetics identifies a genetic link between thinner corneas and an increased risk of glaucoma in humans. The researchers found that the protein POU6F2 plays a crucial role in regulating corneal thickness and may be a potential risk factor for glaucoma.
A study published in the British Journal of Ophthalmology found that drinking hot tea at least once a day is linked to a significantly lower risk of developing glaucoma. The researchers analyzed data from over 10,000 US adults and found that hot tea-drinkers were 74% less likely to have glaucoma compared to non-tea drinkers.
A recent study found that less than one-third of glaucoma patients discuss medication costs with their doctor. High costs are a significant barrier to adherence, and doctors should consider discussing medication costs during visits to prompt a discussion. The study analyzed video recordings of 275 office visits and suggested further re...
A new study supports the view that increased lifetime exposure to estrogen is linked to a reduced risk of developing glaucoma. Women who took estrogen-only hormone replacement therapy after ovary removal had a lower risk of developing glaucoma.
Regular physical activity can significantly reduce the risk of developing glaucoma, with study participants showing a 73% lower risk compared to less active individuals. Exercise has been found to impact eye pressure, a major risk factor for the disease, although more research is needed to confirm the exact relationship.
Researchers at UC Berkeley and University of Toronto have discovered lipid mediators that may halt glaucoma progression. The study found that lipoxins A4 and B4 secreted by astrocytes can stop retinal ganglion cell degeneration, offering a potential treatment for this neurodegenerative disease.
Researchers at UHN's Krembil Research Institute identified LXB4, a unique lipid that protects neurons against glaucoma in preclinical models. This discovery provides hope for devising a new strategy to protect vision in glaucoma patients and may have implications for other neurodegenerative diseases.
Researchers from RUDN University designed new compounds that selectively inhibit human carbonic anhydrase, reducing intraocular pressure and potentially treating glaucoma. The study's findings suggest a promising approach for developing new antiglaucoma drugs by modifying the compound's molecular periphery.
Researchers at Georgia Institute of Technology have identified a rare Y-shape in a protein associated with hereditary glaucoma, which may revolutionize its treatment. The discovery reveals how the Y ties together major components of the protein and could help understand myocilin's role in the eye.
Researchers successfully used CRISPR-Cas9 to eliminate the mutated myocilin protein, which led to lowered intraocular pressure and prevented glaucomatous damage in mouse eyes. This breakthrough study could pave the way for a new therapy to treat myocilin glaucoma in humans.
Researchers at IBS have identified a new mechanism involved in glaucoma development and progression, and found a potential therapeutic option to treat primary open-angle glaucoma. The study highlights the critical role of the angiopoietin-Tie2 system in Schlemm's canal functionality.
The University of North Carolina at Chapel Hill is developing an intervention to empower patients with glaucoma to take a more active role in their treatment. The study aims to improve communication between patients and ophthalmologists, leading to better medication adherence and reduced intraocular pressure.
A new biomarker, GDF15, has been identified as a potential predictor of vision loss in glaucoma patients. The biomarker, which measures stress to cells rather than cell death, was found to be elevated in mice and humans with glaucoma, correlating with disease severity.
Researchers at Medical College of Georgia are exploring the potential of (+)-pentazocine to prevent vision damage in glaucoma patients by activating sigma-1 receptors in astrocytes. The study aims to understand how increased pressure affects astrocyte behavior and develop new therapies to protect neurons.